We'll have to see if a detailed and sensitive analysis of ochraceocentrata yields any traces of, say, β-carbolines on top of a higher psiloc(yb)in potency. As we know, β-carbolines have been found in other Psilocybe species before. It's a bit harder to definitively pinpoint the factors underlying variations in subjective effects.
It's true, but the concentrations at which the beta-carbolines were detected or at tiny trace microgram amounts...for them to become pharmacologically relvant (equivalent to the dosages found in a cup of ayahuasca), psychedelic neurobiologist/chemist/pharmacologist Andrew Gallimore has suggested one would need to consume "
around 30kg of dried mycelia or 3 metric tons of the dried mushrooms". However there are a range of other secondary compounds found in these mushrooms, including tryptamine psilocybin analogues such as baeocystin, norbaeocystin, norpsilocin and aeruginascin, the latter’s breakdown metabolite 4 hydroxy-N,N,N-trimethyltryptamine, terpenes, sesquiterpenes and phenylethylamine derivatives, and I think the research has only really scratched the surface so far. Regarding P. ochraceocentrata in particular, there is no clear chemical "smoking gun" in analyses conducted so far indicating what might be responsible for the perceived differences in effect...however some analyses have shown up baeocystin (at higher levels than tends to be detected in P. cubensis; however this varies), and also a number of
compounds expressing antioxidant and anti-Inflammatory effects (while the species mentioned in this paper is P. natalensis, it is in fact referring to P. ochraceocentrata prior to the latter having been distinguished from the former).
@Jamie01, your own observations regarding P. ochraceocentrata definitely align with mine. I'm soon to (hopefully) have a study paper published where we netted data from quite a few people about their experiences with different species of psilocybin mushrooms, and the effects profile they attribute to different species. While set and setting factors appeared to be the dominant determinants of experiential outcomes (as one might expect), and while it is obviously hard to rule out expectancy effects, the species consumed accounted for a small but reliable and structured share of variance in the subjective-effect factors in spite of all the variation in set and setting factors between individuals. Interestingly, P. ochraceocentrata was consistently rated gentler on somatic distress and challenging experience (also rating lowest on arousal-related physical items such as heightened alertness and dizziness), while the PE/APE varieties of P. cubensis were rated as somewhat harsher. Several less commonly used species were rated above the relative-liking midpoint of the species consumed, whereas P. cubensis was not. Respondents also reported that they perceived species as qualitatively distinct and deliberately selected some for particular effects. Obviously further research will be needed to pin down what chemistry in the mushrooms might be giving rise to these perceived (but quite consistent) differences in effect.